دورية أكاديمية
The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
| العنوان: | The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout. |
|---|---|
| المؤلفون: | Baraf HSB; Rheumatology, Center for Rheumatology and Bone Research, Wheaton, MD, USA.; Rheumatology, George Washington University, Washington DC, USA., Khanna PP; Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA., Kivitz AJ; Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, USA., Strand V; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA., Choi HK; Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA., Terkeltaub R; Rheumatology, Allergy and Immunology Division, San Diego VA Healthcare Service and UCSD, San Diego, CA, USA., Dalbeth N; Bone and Joint Research Group, Department of Medicine, University of Auckland, Auckland, New Zealand., DeHaan W; Selecta Biosciences, Watertown, MA, USA., Azeem R; Selecta Biosciences, Watertown, MA, USA., Traber PG; Selecta Biosciences, Watertown, MA, USA., Keenan RT; Duke University School of Medicine, Durham, NC, USA.; Arthrosi Therapeutics, San Diego, CA, USA. |
| المصدر: | Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2024 Apr 02; Vol. 63 (4), pp. 1058-1067. |
| نوع المنشور: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 100883501 Publication Model: Print Cited Medium: Internet ISSN: 1462-0332 (Electronic) Linking ISSN: 14620324 NLM ISO Abbreviation: Rheumatology (Oxford) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford, UK : Avenel, N.J. : Oxford University Press ; Distributed by Mercury International, c1999- |
| مواضيع طبية MeSH: | Gout* , Stomatitis*/chemically induced , Stomatitis*/drug therapy, Adult ; Humans ; Gout Suppressants/adverse effects ; Gout Suppressants/therapeutic use ; Polyethylene Glycols/adverse effects ; Polyethylene Glycols/therapeutic use ; Symptom Flare Up ; Treatment Outcome ; Urate Oxidase/therapeutic use ; Urate Oxidase/adverse effects ; Uric Acid ; Uricosuric Agents/adverse effects ; Uricosuric Agents/therapeutic use |
| مستخلص: | Objectives: Serum urate (SU) lowering with PEGylated uricases in gout can reduce flares and tophi. However, treatment-emergent anti-drug antibodies adversely affect safety and efficacy and the currently approved PEGylated uricase pegloticase requires twice-monthly infusions. Investigational SEL-212 therapy aims to promote uricase-specific tolerance via monthly sequential infusions of a proprietary rapamycin-containing nanoparticle (ImmTOR) and pegadricase. Methods: COMPARE was a randomized, phase 2, open-label trial of SEL-212 vs pegloticase in adults with refractory gout. SEL-212 [ImmTOR (0.15 mg/kg) and pegadricase (0.2 mg/kg)] was infused monthly or pegloticase (8 mg) twice monthly for 6 months. The primary endpoint was the proportion of participants with SU <6 mg/dl for ≥80% of the time during 3 and 6 months. Secondary outcomes were mean SU, gout flares, number of tender and/or swollen joints and safety. Results: During months 3 and 6 combined, numerically more participants achieved and maintained a SU <6 mg/dl for ≥80% of the time with SEL-212 vs pegloticase (53.0% vs 46.0%, P = 0.181). The percentage reductions in SU levels were statistically greater during months 3 and 6 with SEL-212 vs pegloticase (-73.79% and -47.96%, P = 0.0161). Reductions in gout flare incidence and number of tender and/or swollen joints were comparable between treatments. There were numerical differences between the most common treatment-related adverse events of interest with SEL-212 and pegloticase: gout flares (60.2% vs 50.6%), infections (25.3% vs 18.4%) and infusion-related reactions (15.7% vs 11.5%), respectively. Stomatitis (and related terms) was experienced by eight participants (9.6%) with SEL-212 and none with pegloticase. Stomatitis, a known event for rapamycin, was associated with ImmTOR only. Conclusions: SEL-212 efficacy and tolerability were comparable to pegloticase in refractory gout. This was associated with a substantial reduction in treatment burden with SEL-212 due to decreased infusion frequency vs pegloticase. Clinical Trial Registration: NCT03905512. (© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.) |
| References: | Front Immunol. 2020 May 20;11:969. (PMID: 32508839) Arthritis Care Res (Hoboken). 2020 Jun;72(6):744-760. (PMID: 32391934) Nat Commun. 2022 Jan 12;13(1):272. (PMID: 35022448) Nat Rev Drug Discov. 2011 Jan;10(1):17-8. (PMID: 21193861) FASEB J. 1988 Dec;2(15):3092-6. (PMID: 3192041) Arthritis Rheumatol. 2023 Feb;75(2):293-304. (PMID: 36099211) Nat Nanotechnol. 2016 Oct;11(10):890-899. (PMID: 27479756) Semin Arthritis Rheum. 2021 Apr;51(2):347-352. (PMID: 33601190) Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1182-1189. (PMID: 28752672) Semin Arthritis Rheum. 2020 Jun;50(3S):S31-S38. (PMID: 32620200) J Rheumatol. 2021 May;48(5):767-774. (PMID: 32934137) Biochemistry. 1998 Aug 18;37(33):11651-9. (PMID: 9709003) Arthritis Rheumatol. 2019 Jun;71(6):991-999. (PMID: 30618180) Curr Opin Rheumatol. 2008 Mar;20(2):198-202. (PMID: 18349751) Nat Chem Biol. 2006 Mar;2(3):144-8. (PMID: 16462750) J Clin Rheumatol. 2014 Dec;20(8):427-32. (PMID: 25417679) Postgrad Med. 2016 Sep;128(7):706-15. (PMID: 27558643) JAMA. 2011 Aug 17;306(7):711-20. (PMID: 21846852) Ann Emerg Med. 2006 Apr;47(4):373-80. (PMID: 16546624) |
| معلومات مُعتمدة: | Selecta Biosciences, Inc; AstraZeneca |
| فهرسة مساهمة: | Keywords: SEL-212; gout; nanotechnology; pegadricase; pegloticase; rapamycin; serum urate; uricase |
| سلسلة جزيئية: | ClinicalTrials.gov NCT03905512 |
| المشرفين على المادة: | 0 (Gout Suppressants) R581OT55EA (Pegloticase) 3WJQ0SDW1A (Polyethylene Glycols) EC 1.7.3.3 (Urate Oxidase) 268B43MJ25 (Uric Acid) 0 (Uricosuric Agents) |
| تواريخ الأحداث: | Date Created: 20230714 Date Completed: 20240403 Latest Revision: 20240522 |
| رمز التحديث: | 20240523 |
| مُعرف محوري في PubMed: | PMC10986798 |
| DOI: | 10.1093/rheumatology/kead333 |
| PMID: | 37449908 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1462-0332 |
|---|---|
| DOI: | 10.1093/rheumatology/kead333 |